Physician profile
Richard E Eisenman
NPI 1932107323
$6,655.96
in general payments reported to CMS, 2019-2025
37 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $513 · 2021: $702 · 2022: $1,349 · 2023: $746 · 2024: $1,031 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,049 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.13 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,839.89 | 2019-2025 | |
| Gilead Sciences, INC. | $816.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $617.32 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $607.83 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $556.57 | 2019-2025 | |
| Celgene Corporation | $251.32 | 2019-2024 | Zeposia |
| Genzyme Corporation | $236.81 | 2022-2025 | |
| Vivus LLC | $190.18 | 2019-2025 | Pancreaze, Qsymia |
| Ucb, INC. | $129.39 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $113.89 | 2022-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $107.46 | 2019-2023 | Rebyota |
| Redhill Biopharma INC. | $102.49 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.99 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $97.12 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $93.60 | 2025 | Rezdiffra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $86.94 | 2020-2024 | Zilver Ptx |
| Phathom Pharmaceuticals, INC. | $86.07 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $84.51 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $51.99 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $49.88 | 2025 | Iqirvo |
| Medtronic, INC. | $49.23 | 2022-2023 | Interstim |
| Allergan, INC. | $47.77 | 2019 | |
| Boston Scientific Corporation | $36.84 | 2022 | |
| Intuitive Surgical, INC. | $33.72 | 2020 | |
| Organon LLC | $30.49 | 2023-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.91 | 2023 | |
| Apollo Endosurgery US INC | $25.25 | 2022 | |
| Biocon Biologics INC | $24.52 | 2025 | Yesintek |
| Celltrion USA INC. | $23.38 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $21.71 | 2023 | Linzess |
| Daiichi Sankyo INC. | $19.02 | 2020 | |
| Tersera Therapeutics LLC | $18.34 | 2022 | |
| Alfasigma USA, INC. | $17.71 | 2020 | |
| Shire North American Group INC | $17.02 | 2019 | |
| Ardelyx, INC. | $15.29 | 2023 | Ibsrela |
| Endogastric Solutions, INC | $14.98 | 2023 | Esophyx |
| Olympus America INC. | $14.67 | 2023 | Single Use Grasping Forceps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Eisenman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.